AMG 701 P1/2 Non-Randomized Open-Label Expansion MM
Research payments
$5,814,751
Through program year 2024, $5,814,751 in research payments was reported against AMG 701 P1/2 Non-Randomized Open-Label Expansion MM, across 104 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $451,715 | 10 |
| 2023 | Research | $368,977 | 18 |
| 2022 | Research | $1,380,934 | 25 |
| 2021 | Research | $3,574,179 | 49 |
| 2020 | Research | $38,947 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ruben Niesvizky New York, NY Named on 10 payments
- Prashant Kapoor Rochester, MN Named on 8 payments
- Sikander Ailawadhi Jacksonville, FL Named on 7 payments
- Suzanne Lentzsch New York, NY Named on 5 payments
- Deepu Madduri New York, NY Named on 5 payments
- Andrzej Jakubowiak Chicago, IL Named on 4 payments
- Saurabh Chhabra Milwaukee, WI Named on 4 payments
- Douglas Sborov Salt Lake City, UT Named on 4 payments
- Hans Lee Houston, TX Named on 4 payments
- Ravi Vij Saint Louis, MO Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.